Publications

363 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period
Period

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:
  1. GVS advice on the reassessment of tafamidis (Vyndaqel®)

    The Zorginstituut recommends not to include tafamidis (Vyndaqel®) in the GVS, unless a price reduction of at least 50% can be ...

    Report | 11-08-2021

  2. Advice on the reassessment of axicabtagene ciloleucel (Yescarta®)

    The National Health Care Institute has carried out the reassessment of axicabtagene ciloleucel (Yescarta®).

    Report | 26-07-2021

  3. GVS advice on ferrimaltol (Feraccru®) for treating iron deficiency

    Zorginstituut Nederland recommends that ferrimaltol (Feraccru®) should not be included in the Medicine Reimbursement System ...

    Report | 26-07-2021

  4. GVS advice on subcutaneous buprenorphine (Buvidal®)

    Zorginstituut Nederland has completed its assessment whether the product subcutaneous buprenorphine (Buvidal®) is interchangeable ...

    Report | 21-07-2021

  5. Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®)

    The National Health Care Institute has completed its assessment whether betibeglogene autotemcel (Zynteglo®) can be included in ...

    Report | 21-07-2021

  6. Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma

    Zorginstituut Nederland has completed its assessment whether avelumab (Bavencio®) can be included in the insured package. ...

    Report | 21-07-2021

  7. Package advice on entrectinib (Rozlytrek®) for the treatment of ROS1 fusion-positive advanced non-small cell lung cancer

    Zorginstituut Nederland has completed its assessment whether entrectinib (Rozlytrek®) can be included in the insured package. The ...

    Report | 21-07-2021

  8. GVS advice for cladribine (Mavenclad®) – extension of further conditions

    The National Health Care Institute has completed its reassessment whether the further conditions of cladribine (Mavenclad®) could ...

    Report | 05-07-2021

  9. GVS assessment of calcifediol (Hidroferol®)

    Zorginstituut Nederland has completed its assessment whether calcifediol (Hidroferol®) is interchangeable with a medicine already ...

    Report | 01-07-2021

  10. Package advice niraparib (Zejula®)

    Zorginstituut Nederland has completed its assessment whether niraparib (Zejula®) can be included in the insured package. ...

    Report | 24-06-2021